Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Should You Sell This Stock After Another Regulatory Headwind?
06:09am, Friday, 06'th Oct 2023
Eli Lilly set out to launch four new products this year, but it is unlikely to do so. The company's regulatory roadblocks aren't deal-breakers for its medicines.
What Are The Best Stocks To Invest In? 2 Healthcare Stocks To Know
10:38am, Thursday, 05'th Oct 2023
Healthcare stocks to watch right now.
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
05:50am, Thursday, 05'th Oct 2023
There have been relatively few big winners among pharma stocks so far in the 2020s. One big pharma stock stands out as the clear leader by roughly tripling over the last nearly four years.
Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing
06:47pm, Wednesday, 04'th Oct 2023
Eli Lilly (LLY) concluded the recent trading session at $531.46, signifying a +1.19% move from its prior day's close.
Lilly (LLY) to Buy POINT Biopharma, Strengthen Cancer Portfolio
09:46am, Wednesday, 04'th Oct 2023
Eli Lilly's (LLY) acquisition of POINT Biopharma, if successfully closed, is likely to bolster its portfolio of cancer drugs.
Eli Lilly exec behind diabetes blockbuster set retire
08:34am, Wednesday, 04'th Oct 2023
Mike Mason, the executive vice president and president of Lilly Diabetes & Obesity at Eli Lilly and Co (NYSE:LLY), is set to retire at the end of this year after a 34-year tenure with the pharmaceutic
Eli Lilly's head of diabetes and obesity unit to retire
07:06am, Wednesday, 04'th Oct 2023
Eli Lilly and Co said on Wednesday that the head of its diabetes and obesity division, Mike Mason, will retire by the end of the year after more than three decades with the drugmaker.
Why Eli Lilly Stock Was Looking Sickly Today
06:33pm, Tuesday, 03'rd Oct 2023
The pharmaceutical giant signed a deal to acquire cancer therapy developer Biopharma Global. Its asset-to-be is a developer of precision cancer therapies.
Eli Lilly Buys POINT Biopharma to Boost Its Cancer-Fighting Therapies
12:00pm, Tuesday, 03'rd Oct 2023
Shares of POINT Biopharma Global (PNT) skyrocketed over 80% in early trading on Tuesday after Eli Lilly (LLY) agreed to buy the radiopharmaceutical firm for $1.4 billion to expand its cancer-fighting
Eli Lilly Stock Cools Despite Big Cancer Investment
10:43am, Tuesday, 03'rd Oct 2023
Eli Lilly And Co (NYSE: LLY ) stock is down 2.5% to trade at $525.97 at last check, after the pharma company announced the acquisition of Point Biopharma Global (PNT) for $1.4 billion in an all-ca
Eli Lilly Acquiring Cancer Therapy Developer For $1.4 Billion—A Nearly 90% Premium
10:21am, Tuesday, 03'rd Oct 2023
American pharmaceutical company Eli Lilly plans to acquire cancer therapy firm Point Biopharma Global, the companies announced Tuesday, an expansion that comes as manu
Point Biopharma shares storm ahead 84% after Eli Lily's $1.4bn bid
09:05am, Tuesday, 03'rd Oct 2023
Shares in Point Biopharma Global jumped 84% following the announcement that pharmaceutical giant Eli Lilly and Co (NYSE:LLY) will acquire the company for $1.4 billion (£1.03 billion). The acquisition
Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection
09:01am, Tuesday, 03'rd Oct 2023
Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.
Eli Lilly to Buy Point Biopharma for $1.4 Billion
07:34am, Tuesday, 03'rd Oct 2023
Eli Lilly will acquire radiopharmaceutical company Point Biopharma Global for $12.50 a share.
Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion
07:07am, Tuesday, 03'rd Oct 2023
Eli Lilly and Co will buy cancer therapy developer Point Biopharma Global for $1.4 billion, the companies said on Tuesday.
